GCL
AVDL

Glazer Capital LLC’s Avadel Pharmaceuticals AVDL Stock Holding History

Glazer Capital LLC’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,000
Closed -$388K – 486
2025
Q4 		$388K Buy
+18,000
New +$349K 0.01% 252

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Glazer Capital LLC's AVDL Position: Q1 2026 in Review

Glazer Capital LLC sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 18,000 shares — an estimated $388K sold.

Glazer Capital LLC first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $388K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Glazer Capital LLC reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Glazer Capital LLC sold 18,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $388K.
  • Glazer Capital LLC first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Glazer Capital LLC's Avadel Pharmaceuticals position peaked at $388K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.